2022
Treatment patterns and medical costs of metastatic breast cancer care in the United States.
Chehayeb R, Hood A, Mougalian S, Lustberg M, Wang S, Greenup R, Pusztai L, Kunst N. Treatment patterns and medical costs of metastatic breast cancer care in the United States. Journal Of Clinical Oncology 2022, 40: e18834-e18834. DOI: 10.1200/jco.2022.40.16_suppl.e18834.Peer-Reviewed Original ResearchMetastatic breast cancerTreatment patternsTreatment costsDiagnosis of MBCSocietal perspectiveHormone receptor statusBreast cancer careDays of diagnosisDe-identified databaseAverage wholesale priceElectronic health recordsMBC patientsMBC diagnosisReceptor statusCancer careInvasive cancerTriple NegativeClinical trialsReceptor subtypesPatient levelBreast cancerHuman epidermal growth factorPayer perspectiveDrug costsEpidermal growth factor
2019
Examining the cost-effectiveness of baseline left ventricular function assessment among breast cancer patients undergoing anthracycline-based therapy
Abu-Khalaf MM, Safonov A, Stratton J, Wang S, Hatzis C, Park E, Pusztai L, Gross CP, Russell R. Examining the cost-effectiveness of baseline left ventricular function assessment among breast cancer patients undergoing anthracycline-based therapy. Breast Cancer Research And Treatment 2019, 176: 261-270. PMID: 31020471, DOI: 10.1007/s10549-019-05178-z.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioEquilibrium radionuclide angiographyCardiac risk factorsBreast cancer patientsVentricular function assessmentRisk factorsAbnormal LVEFBaseline LVEFCancer patientsBreast cancerFunction assessmentPotential cardiac risk factorsSelf-reported risk factorsAnthracycline-based therapyLeft ventricular function assessmentCoronary artery diseaseCost-effectiveness ratioArtery diseaseTrastuzumab therapyCardiac screeningPatient populationRadionuclide angiographyCardiotoxicity riskPayer perspectiveRetrospective analysis